XTRA:BAYNPharmaceuticals
Evaluating Bayer (XTRA:BAYN) After New KERENDIA And NUBEQA Clinical And Regulatory Milestones
Bayer (XTRA:BAYN) is back in focus after a cluster of drug news, including fresh KERENDIA kidney data, an FDA Priority Review for a new KERENDIA indication, and updated NUBEQA cognitive results in prostate cancer.
See our latest analysis for Bayer.
Despite the steady stream of KERENDIA and NUBEQA updates, Bayer’s short term share price return is still down over the past month and quarter. The 1 year total shareholder return of 37.44% and weaker 3 and 5 year total shareholder returns point to...